CAR-T Meeting 2023 | Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, highlights ongoing research exploring the use of Bruton’s tyrosine kinase (BTK) inhibitors as a strategy to enhance the efficacy of CAR-T cells. Prof. Gribben explains that several clinical studies have evaluated ibrutinib due to its ability to target interleukin-2 inducible T-cell kinase (ITK), and further comments on the possibility of exploring other second-generation BTK inhibitors, including acalabrutinib and zanubrutinib. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
